Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E0LQ
|
||||
| Former ID |
DAP000318
|
||||
| Drug Name |
Thiothixene
|
||||
| Synonyms |
Navan; Navane; Navaron; Orbinamon; Thiothixine; Tiotixene; Tiotixeno; Tiotixenum; Thiothixene hydrochloride; P 4657B; CP 12252-1; Cis-Thiothixene; Navane (TN); P-4657 B; P-4657A; P-4657B; Thiothixene (USP); Thiothixene (Z); Thiothixene Hydrochloride (base); Thiothixene [USAN:BAN]; Tiotixene (JAN); Tiotixeno [INN-Spanish]; Tiotixenum [INN-Latin]; Trans-Thiothixene; P-4657-B; CP-12,252-1; CP-12,252-1 base; {2-(Dimethylsulfamoyl)-[9-(4-methyl-1-piperazinyl)propylidene]thiox} anthene; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thiaxanthene-2-sulfonamide; N,N-Dimethyl-9-[3-(4-methyl-1-piperazinyl)propylidene]thioxanthene-2-sulfonamide; N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Trans-N,N-Dimethyl-9-(3-(4-methyl-piperazinyl)propylidene)thioxanthene-2-sulfonamide; Cis-N,N-Dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)thioxanthene-2-sulfonamide; N,N-Dimethyl-9-(3-(4-methylpiperazin-1-yl)propylidene)-9H-thioxanthene-2-sulphonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide; (9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide; (E)-Thiothixene; 2-(Dimethylsulfamoyl)-(9-(4-methyl-1-piperazinyl)propylidene)thioxanthene
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia [ICD9: 295; ICD10:F20] | Approved | [1], [2] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
Pfizer Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H29N3O2S2
|
||||
| InChI |
InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8-
|
||||
| InChIKey |
GFBKORZTTCHDGY-UWVJOHFNSA-N
|
||||
| CAS Number |
CAS 5591-45-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
616474, 7847440, 7980778, 9208389, 10527275, 11532885, 12013417, 14759539, 44891823, 46505564, 47217055, 47736752, 47811025, 48035404, 48110727, 48334780, 50054592, 50054593, 50111253, 57408892, 76674035, 81049375, 93167171, 103358973, 110097312, 124750269, 124799400, 126673294, 134221874, 134337630, 135022512, 135651260, 137005727, 140637626, 151990180, 160964859, 175268220, 179148852, 184580899, 184590634, 223667992, 223704321, 226420796, 241073624, 241180615, 249983475, 252347478, 252401248, 252451220, 252655323
|
||||
| SuperDrug ATC ID |
N05AF04
|
||||
| SuperDrug CAS ID |
cas=003313266
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Antagonist | [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070600. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 212). | ||||
| REF 3 | Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.